Second-line regorafenib for advanced RAS-mutant colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

STREAM-2 is an open-label, randomized, multicenter phase 2 trial enrolling 60 patients with RAS‑mutant metastatic colorectal cancer who progress after first-line therapy but have favorable prognostic features (PFS > 6 months in first line and/or a single metastatic site). Patients are randomized 1:1 to receive either regorafenib with a dose‑escalation strategy given in 4-week cycles or a standard second-line treatment chosen by the investigator given in 2-week cycles. Tumor measurements are documented at baseline and reassessed regularly (every 8 weeks), and patients continue treatment until progression, unacceptable toxicity, or other discontinuation criteria. All patients enter follow-up after treatment and are followed until death with subsequent therapies recorded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent to study procedures and to correlative studies.
2. Either sex aged ≥ 18.
3. Histologically proven of colorectal adenocarcinoma.
4. Diagnosis of metastatic disease.
5. RAS mutant at initial diagnosis assessed at local centers according with a validated method defined by EMA and known MMR/MSI status.
6. Achieved a PFS in first line \> 6 months with chemotherapy in combination to antiangiogenic treatment OR with one metastatic site at study entry
7. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1 at study entry.
8. Imaging-documented measurable disease, according to RECIST 1.1 criteria.
9. Estimated life expectancy of more than 12 weeks
10. Adequate bone marrow hematological function: absolute neutrophil count (ANC) ≥ 1.5 x 109/L and platelet count ≥ 100 x 109/L and hemoglobin ≥ 9 g/dL.
11. Adequate liver function: total bilirubin ≤ 1.5 x upper limit of normal (ULN) or ≤ 2 (in case of biliary stent) and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 5 X ULN.
12. Adequate renal function: serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min in males and ≥50 mL/min in females (calculated according to Cockroft-Gault formula).
13. Electrolytes (i.e. magnesium, calcium, sodium and potassium) within laboratory normal range.
14. Known dihydropyrimidine dehydrogenase (DPYD) activity is mandatory. Additional analysis of polymorphisms uridine diphosphate-glycosyltransferase 1 (UGT1A1) enzyme is recommended but not mandatory.

Exclusion Criteria:

1. Prior malignancy within five years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
2. Any contraindication to regorafenib.
3. Not received immunotherapy if dMMR or MSI-H.
4. Major surgical intervention within 4 weeks prior to enrollment.
5. Pregnancy and breast-feeding.
6. Any brain metastasis.
7. Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study, or which would jeopardize compliance with the protocol, or would interfere with the results of the study.
8. History of poor co-operation, non-compliance with medical treatment, unreliability or any condition that may impair the patient's understanding of the Informed consent form.
9. Participation in any interventional drug or medical device study within 30 days prior to treatment start.
10. Sexually active males and females (of childbearing potential) unwilling to practice contraception (barrier contraceptive measure or oral contraception) during the study and until 6 months after the last trial treatment.
11. Complete deficiency of activity of dihydropyrimidine dehydrogenase (DPYD)

Where it's running

• Istituto Nazionale Tumori | "Fondazione Pascale"
  Naples, Italy, Italy Recruiting

Study contacts

• Study coordinator: Antonio Avallone, MD
• Email: a.avallone@istitutotumori.na.it
• Phone: 003908117770357

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• Combination of balstilimab, botensilimab, and agenT-797 in pMMR colorectal cancer with liver metastases

  This trial tests whether a three-drug combination can help adults with metastatic, MSS colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Scripps Health · La Jolla, California · NCT07550088

• Dual-target CAR-NK therapy for advanced colorectal cancer with CEA, GUCY2C, or HER2 markers

  This trial tests an off-the-shelf CAR-NK cell treatment that targets two tumor markers to see if it can shrink tumors in adults with advanced or metastatic colorectal cancer whose tumors express those markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07462650

• COLONYVAQ™: personalized quantum‑classical neoantigen peptide vaccine combined with chemotherapy and nivolumab for MSS stage III colorectal cancer

  This trial will test a personalized neoantigen peptide vaccine guided by quantum‑classical AI together with standard oxaliplatin‑based chemotherapy and nivolumab in patients with completely resected, microsatellite‑stable stage III colorectal cancer.

  Recruiting Early Phase 1 Biogenea Pharmaceuticals Ltd. · Thessaloniki · NCT07328087

• ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer

  This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.

  Recruiting Phase 1/2 Anbogen Therapeutics, Inc. · Liverpool, New South Wales and 14 other locations · NCT07244705

• Hybrid hospital and community delivery of hepatic artery infusion chemotherapy for liver metastases and intrahepatic cholangiocarcinoma

  This Phase 2 trial will test whether giving floxuridine through a surgically implanted hepatic artery infusion pump — with follow-up care either at a major hospital or by local community oncologists — is safe and practical for adults with colorectal cancer liver metastases or unresectable intrahepatic cholangiocarcinom

  Recruiting Phase 2 University of Kentucky · Lexington, Kentucky · NCT07201519

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.